Who we are
Our aim is to improve the lives of people living with diabetes, obesity and other cardiometabolic diseases through the development of superior therapeutics that address areas of high unmet patient need in high value markets.
Our proven technology platform provides us with multiple options to drive value for our partners, shareholders and other stakeholders.
We have a broad and de-risked product portfolio and pipeline:
- AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin with demonstrated PK/PD superiority over the gold standard non-concentrated insulins available today
- Developing a potentially game-changing novel oral peptide delivery technology platform, leveraging existing Arecor expertise with minimal capital investment
We partner with leading pharmaceutical, biotech and medtech companies:
- Co-development agreement with Sequel Med Tech to undertake preparatory work for Phase 2 clinical trial for combined AT278 /Insulin Pump programme
- Continued revenue generation and significant future upside potential
Our validated technology
- World-leading Arestat® drug formulation technology platform
- Applicable to high-value biologics, including peptides, as well as future potential applications such as oral delivery, mRNA and cell & gene therapies
- Third party validation and license revenue from diversified customer base across disease areas
- Extensive IP protection with >100 granted patents in US, Europe and other key territories